Synthesis and evaluation of isomeric (17α,20E)-11β-methoxy-21- (trifluoromethylphenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols as ERα-hormone binding domain ligands: Effect of the methoxy group on receptor binding and uterotrophic growth

Journal of Medicinal Chemistry

Volumn 50, Issue 3, 2007, Pages 472-479

  Hanson, Robert N ^a   Tongcharoensirikul, Pakamas ^a   Dilis, Robert ^a   Hughes, Alun ^b   DeSombre, Eugene R ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA METHOXY 21 (2 TRIFLUOROMETHYLPHENYL) 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17BETA DIOL; 11BETA METHOXY 21 (3 TRIFLUOROMETHYLPHENYL) 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17BETA DIOL; 11BETA METHOXY 21 (4 TRIFLUOROMETHYLPHENYL) 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17BETA DIOL; 11BETA METHOXY 21 (TRIFLUOROMETHYLPHENYL) 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17BETA DIOL; 11BETA METHOXY 21 PHENYL 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17BETA DIOL; ESTROGEN RECEPTOR ALPHA; LIGAND; METHOXY GROUP; METHYL GROUP; MOXESTROL; PREGNANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HORMONE BINDING; ISOMER; MOLECULAR MODEL; NONHUMAN; PROTEIN DOMAIN; PROTEIN STABILITY; RAT; UTERUS GROWTH;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; LIGANDS; MODELS, MOLECULAR; NORPREGNATRIENES; PROTEIN STRUCTURE, TERTIARY; RADIOLIGAND ASSAY; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; UTERUS;

EID: 33846960213     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060940f     Document Type: Article

References (53)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J. Cancer statistics, 2006. CA - Cancer J. Clin. 2006, 56, 106-130.
2. Gradishar, W. J.; Jordan, V. C. Hormonal therapy for breast cancer An update. Hematol. Oncol. 1999, 13, 435-455.
3. Macgregor, J. I.; Jordan, V. C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 1998, 50, 151-196.
4. Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J. Med. Chem. 2003, 46, 883-908.
5. Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 2003, 46, 1081-1111.
6. Simpson, E. R.; Davis, S. R. Minireview: Aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endo crinology 2001, 142, 4589-4594.
7. Bhatnagar, A. S.; Miller, W. R. Pharmacology of inhibitors of estrogen biosynthesis. Handb. Exp. Pharmacol. 1999, 135/11, 223-230.
8. Evans, R. M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889-895.
9. Tsai, M. J.; O'Malley, B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994, 63, 451-86.
10. Nilsson, S.; Gustafsson, J.-A. Biological role of estrogen and estrogen receptors. Crit. Rev. Biochem. Mol. Biol. 2002, 37, 1-28.
11. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
12. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
13. Tanenbaum, D. M.; Wang, Y.; Williams, S. P.; Sigler, P. B. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5998-6003.
14. Pike, A. C. W.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A.-G.; Engstrom, O.; Ljunggren, J.; Gustafsson, J.-A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18, 4608-4618.
15. Saunders, P. T. Oestrogen receptor beta (ER beta). Reviews of reproduction 1998, 3, 164-171.
16. Gustafsson, J. A. Estrogen receptor beta - A new dimension in estrogen mechanism of action. J. Endocrinol. 1999, 163, 379-383.
17. Harris, H. A.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 2002, 143, 4172-4177.
18. McKenna, N. J.; O'Malley, B. W. From ligand to response: generating diversity in nuclear receptor coregulator function. J. Steroid Biochem. Mol. Biol. 2000, 74, 351-356.
19. Glass, C. K.; Rose, D. W.; Rosenfeld, M. G. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 1997, 9, 222-232.
20. McKenna, N. J.; Lanz, R. B.; O'Malley, B. W. Nuclear receptor coregulators: Cellular and molecular biology. Endocr. Rev. 1999, 20, 321-344.
21. Ojasoo, T.; Raynaud, J.-P. Steroid hormone receptors. In Comprehensive Medicinal Chemistry; Hansch, C., Sammes, P. G., Taylor, J. B., Eds.: Pergamon Press: New York, N.Y, 1990; Vol 3, pp 1175-1226.
22. Jones, C. D.; Jevnikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]-thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl] -[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 1984, 27, 1057-1066.
23. Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips. D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)] benzo[b]thiophene: A novel, highly potent, selective estrogen receptor modulator. J. Med. Chem. 1997, 40, 1407-1416.
24. Labrie, F.; Labrie, C.; Belanger, A.; Simard, J.; Gauthier, S.; Luu-The, V.; Merand, Y.; Giguere, V.; Candas, B.; Luo, S.; Martel, C.; Singh, S. M.; Fournier, M.; Coquet, A.; Richard, V.; Charbonneau, R.; Charpenet, G.; Tremblay, A.; Tremblay, G.; Cusan, L.; Veilleux, R. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol. 1999, 69, 51-84.
25. Weatherman, R. V.; Carroll, D. C.; Scanlan, T. S. Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site. Bioorg. Med. Chem. Lett. 2001, 11, 3129-3131.
26. Rosati, R. L.; Jardine, P. D. S.; Cameron, K. O.; Thompson, D. D.; Ke. H. Z.; Toler, S. M.; Brown, T. A.; Pan, L. C.; Ebbinghaus, C. F.; Reinhold, A. R.; Elliott, N. C.; Newhouse, B. N.; Tjoa, C. M.; Sweetnam, P. M.; Cole, M. J.; Arriola, M. W.; Gauthier, J. W.; Crawford, D. T.; Nickerson, D. F.; Pirie, C. M.; Qi, H.; Simmons, H. A.; Tkalcevic, G. T. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J. Med. Chem. 1998, 41, 2928-2931.
27. Bury, P. S.; Christiansen, L. B.; Jacobsen, P.; Jorgensen, A. S.; Kanstrup, A.; Naerum, L.; Bain, S.; Fledelius, C.; Gissel, B.; Hansen, B. S.; Korsgaard, N.; Thorpe, S. M.; Wassermann, K. Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg. Med. Chem. Lett. 2001, 10, 125-145.
28. Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J. A. The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997, 62, 268-303.
29. Gao, H.; Katzenellenbogen, J. A.; Garg, R.; Hansch, C. Comparative QSAR analysis of estrogen receptor ligands. Chem. Rev. 1999, 99, 723-744.
30. Ali, H.; van Lier, J. E. Synthesis of nitrile derivatives of estrogens. Bioorg. Med. Chem. Lett. 2002, 12, 2847-2849.
31. Napolitano, E.; Fiaschi, R.; Hanson. R. N. Structure-activity relationships of estrogenic ligands: Synthesis and evaluation of (17α,20E)- and (17α,20Z)-21-halo-19-norpregna-1,3, 5(10),20-tetraene-3,-17β-diols. J. Med. Chem. 1991, 34, 2754-2759.
32. Napolitano, E.; Fiaschi, R.; Herman, L. W.; Hanson, R. N. Synthesis and estrogen receptor binding of (17α,20E)- and (17α,20Z)- 21-phenylthio- and 21-phenylseleno-19-norpregna-1,3,5(10),20-tetraene-3, 17β-diols. Steroids 1996, 61, 384-389.
33. Hanson, R. N.; Herman, L. W.; Fiaschi, R.; Napolitano, E. Stereochemical probes for the estrogen receptor: synthesis and receptor binding of (17α,20E/Z)-21-phenyl-19-norpregna-1,3,5-(10),20-tetraene-3, 17β-diols. Steroids 1996, 61, 718-722.
34. Hanson, R. N.; Lee, C. Y.; Friel, C. J.; Dilis, R.; Hughes, A.; DeSombre, E. R. Synthesis and evaluation of 17α-20E-21-(4-substituted phenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols as probes for the estrogen receptor hormone binding domain. J. Med. Chem. 2003, 46, 2865-2876.
35. Hanson, R. N.; Friel, C. J.; Dilis, R.; Hughes, A.; DeSombre, E. R. Synthesis and evaluation of (17α,20Z)-21-(4-substituted phenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols as ligands for the estrogen receptor alpha hormone binding domain: Comparison with 20E-isomers. J. Med. Chem. 2005, 48, 4300-4311.
36. Mobley, J. A.; L'Esperance, J. O.; Wu, M.; Friel, C. J.; Hanson, R. N.; Ho, S.-M. The novel estrogen 17α-20Z-21-[(4-amino)phenyl]-19-norpregna-1, 3,5(10),20-tetraene-3,17β-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro. Mol. Cancer Ther. 2004, 3, 587-596.
37. Hanson, R. N.; Lee, C. Y.; Friel, C.; Hughes, A.; DeSombre, E. R. Evaluation of 17α-E-(trifluoromethylphenyl)vinyl estradiols as novel estrogen receptor ligands. Steroids 2003, 68, 143-148.
38. Azadian-Boulanger, G.; Bertin, D. Synthesis and uterotropic activity of 11β-methoxyestradiol, 11β-methoxyestriol, and 11β-methoxy- 17α-ethynylestradiol. Chim. Ther. 1973, 8, 451-454.
39. Belanger, A.; Philibert, D.; Teutsch, G. Regio and stereospecific synthesis of 11β-substituted 19-norsteroids. Influence of 11β-substitution on progesterone receptor affinity - (1). Steroids 1981, 37, 361-382.
40. Pomper, M. G.; VanBrocklin, H.; Thieme, A. M.; Thomas, R. D.; Kiesewetter, D. O.; Carlson, K. E.; Mathias, C. J.; Welch, M. J.; Katzenellenbogen, J. A. 11β-Methoxy-, 11β-ethyl, and 17α-ethynyl-substituted 16α-fluoroestradiols: Receptor-based imaging agents with enhanced uptake efficiency and selectivity. J. Med. Chem. 1990, 33, 3143-3155.
41. Quivy, J.; Leclercq, G.; Deblaton, M.; Henrot, P.; Velings, N.; Norberg, B.; Evrard, G.; Zeicher, M. Synthesis, structure, and biological properties of Z-17α-(2-iodovinyl)-11β-chloromethyl estradiol-17β (Z-CMIV), a high affinity ligand for the characterization of estrogen receptor-positive tumors. J. Steroid Biochem. Mol. Biol. 1996, 59, 103-117.
42. Poupaert, J. H.; Lambert, D. M.; Vamecq, J.; Abul-Hajj, Y. J. Molecular modeling studies on 11β-aminoethoxyphenyl and 7α-aminoethoxyphenyl estradiols. Evidence suggesting a common hydrophobic pocket in estrogen receptor. Bioorg. Med. Chem. Lett. 1995, 5, 839-842.
43. Hanson, R. N.; Napolitano, E.; Fiaschi, R. Novel high-affinity steroidal estrogenic ligands: synthesis and receptor binding of 11β-vinyl-17α- [(E/Z)-(phenylselenovinyl)]estradiols. Steroids 1998, 63, 479-483.
44. Hanson, R. N.; Napolitano, E.; Fiaschi, R. Synthesis and evaluation of 11β-substituted 21-chloro/iodo-(17α,20E/Z)-19-norpregna-1,3,5- (10),20-tetraene-3,17beta-diols: High-affinity ligands for the estrogen receptor. J. Med. Chem. 1998, 41, 4686-4692.
45. Zhang, J.-X.; Labaree, D. C.; Hochberg, R. B. Nonpolar and short side chain groups at C-11b of estradiol result in antiestrogens. J. Med. Chem. 2005, 48, 1428-1447.
46. Métivier, R.; Penot, G.; Flouriot, G.; Pakdel, F. Synergism between ERα transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: Requirement for the AF-1 a-helical core and for a direct interaction between the N- and C-terminal domains. Mol. Endocrinol. 2001, 15, 1953-1970.
47. Burakov, D.; Crofts, L. A.; Chang, C.-P. B.; Freedman, L. P. Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor. J. Biol. Chem. 2002, 277, 14359-14362.
48. Iannone, M. A.; Simmons, C. A.; Kadwell, S. H.; Svoboda, D. L.; Vanderwall, D. E.; Deng, S.-J.; Consler, T. G.; Shearin, J.; Gray, J. G.; Pearce, K. H. Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol. Endocrinol. 2004, 18, 1064-1081.
49. Harris, H. A.; Bapat. A. R.; Gonder, D. S.; Frail, D. E. The ligand binding profiles of estrogen receptors alpha and beta are species dependent. Steroids 2002, 67, 379-384.
50. Seielstad, D. A.; Carlson, K. E.; Katzenellenbogen, J. A.; Kushner, P. J.; Greene, G. L. Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli. Mol. Endocrinol. 1995, 9, 647-58.
51. Insight 11 97.2/ Discover 2.9.7 (MSI, Inc., San Diego), 2000.
52. DeLisle, R. K.; Yu, S.-J.; Nair, A. C.; Welsh, W. J. Homology modeling of the estrogen receptor subtype b (ER-b) and calculation of ligand binding affinities. J. Mol. Graphics Modell. 2001, 20, 155-167.
53. Nair, A. C.; Miertus, S.; Tossi, A.; Romeo, D. A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogs. Biochem. Biophys. Res. Commun. 1998, 242, 545-551.